Trinity Biotech plc (ADR) (TRIB)

michaeltbryant (< 20) Submitted: 6/11/2009 9:51:07 PM : Start Price: $4.35 TRIB Score: -23.57

The company reported positive results for drug candidate. Catalyst. Plus it has another promising drug in its pipeline that is unmatched by rivals.

maryandtommy (22.58) Submitted: 9/8/2008 10:55:35 AM : Start Price: $4.54 TRIB Score: +6.97

I work in health care, and I believe point of care diagnostics is the wave of the future, as it has clear advantages for both the patient and the heatlth care industry, from convenience to time and cost efficiency.

wracky (< 20) Submitted: 7/31/2008 10:03:21 PM : Start Price: $3.29 TRIB Score: -34.72

It's a BS company

AhWu (83.75) Submitted: 4/15/2008 10:01:59 PM : Start Price: $4.60 TRIB Score: +2.82

I picked this up totally at the wrong time (pretty much exactly 10 days too early), so I got hammered when the executive recently heavily discounted their stock to raise capital to finish paying off their 2006 purchase of the haemostasis business of French firm Biomerieux. As a result for the rest of you lucky investors out there, however, the stock is now sitting pretty at around 20% down from what I already considered a heck of a deal. I really wish I had the opportunity to buy into this company for the first time at this price and ride it from here.

Also, if you want more convincing, O'Caoimh, the executive chairman, just picked up 250,000 shares to supplement the 100,000 he bought on March 20. Not that insider trading necessarily means anything, but it's always nice to see executives having just bought over $1 milliion in their own company. http://www.forbes.com/markets/feeds/afx/2008/04/15/afx4890516.html

I see serious gains over the next year or two, maybe not all the way back up to to around 20, but at least to 10 (+ 300%). Here's hoping I'm right.

Rocket042001 (29.83) Submitted: 4/2/2008 8:45:42 PM : Start Price: $4.60 TRIB Score: +5.04

Undervalued.

slbushey (42.51) Submitted: 3/23/2008 2:10:46 PM : Start Price: $4.54 TRIB Score: +4.52

The opportunities in this field are phenominal as the development of the laser knife has cracked the industry wide open. With so many advancements in technology advancing the causes in medical diagnostics as long as they don't invest in the Edsel they should continue to grow and provide a return on investment.

cold5starstocks (56.80) Submitted: 2/29/2008 11:22:12 PM : Start Price: $4.60 TRIB Score: +2.82

Experiment time... I will pick whatever stocks that are on the cold 5 star list on the last trading day of each month. There is no research involved other what is on the cold 5 star list at the end of each month. Each pick will be for one year. Lets see where this goes...

pro9185 (87.77) Submitted: 1/20/2008 8:12:19 PM : Start Price: $5.91 TRIB Score: -20.78

extremely undervalued.

skeemi (< 20) Submitted: 10/31/2007 2:54:02 PM : Start Price: $9.24 TRIB Score: -30.34

45% growth rate with an unlimited potential...if there is ever an unknown pandemic(praying that this will not be so), TRIB will be a scorcher. BTW: I have owned this stock(bought as a penny stock) for about 8 years and I am waiting for the big bounce which I anticipate in the next year or so. I refuse to sell this one!

Best fundamentals of all the stock I bought before the Bubble burst...only one still invested. Catch it if it falls blow $9 then hold for retirement(I hope).

trentschoneweis (53.17) Submitted: 10/27/2007 2:05:27 AM : Start Price: $9.31 TRIB Score: -30.77

mostly a solid company that had a really bad day. also any stock with a price/book less than one is basically guaranteed.

sallyshooter (20.70) Submitted: 10/10/2007 10:45:35 PM : Start Price: $10.68 TRIB Score: -34.95

9 of 10
5 of 5

JedediahSmith (< 20) Submitted: 10/4/2007 7:10:59 PM : Start Price: $10.82 TRIB Score: -36.34

There is good growth potential for rapid diagnostics, especially in developing countries where AIDS continues to be a problem. TRIB is well positioned to benefit from this growth. TRIB is capturing new market share in NA and EU markets as well.

TRIB has a successful record of growth both organic and via acquisition.

TRIB has also shown consistent revenue and EBITDA growth, indicating that management has been successful in keeping costs in line with growth.

pennysplants (99.28) Submitted: 8/31/2007 8:36:24 AM : Start Price: $10.28 TRIB Score: -38.52

Diagnostics. Micro-Cap. Under the radar. Major product launches expected shortly. Ireland. Global market. Expect 20% annual growth. Fairly/under valued.

Sticky Note Follows.

DUBLIN, IRELAND--(MARKET WIRE)--Aug 9, 2007 -- Trinity Biotech plc (NasdaqGS:TRIB - News) (DUBLIN: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2007.

Revenues for the quarter increased 37.1% to US$37.4 million compared to US$27.3 million in the same period last year, in part reflecting the acquisition of bioMerieux in June 2006. Operating profit before share option expenses has increased from US$2.3 million to US$4.1 million or 10.9% of revenues. Profit after tax for quarter 2 increased from US$2.1 million in 2006 to US$2.6 in 2007 representing an increase of 23.6%.

Revenues for the six months by key product area were as follows :

H1 2006 H1 2007
US$000 US$000 % Increase

Clinical Chemistry 7,502 8,345 11.2%
Haemostasis 14,782 32,494 119.8%
Infectious Diseases 21,027 20,195 (4.0)%
Point of Care 8,716 13,112 50.4%
Total 52,027 74,146 42.5%

Revenues for the six months by geographic location were as follows :

H1 2006 H1 2007
US$000 US$000 % Increase

USA 24,948 33,851 35.7%
Europe 14,274 23,056 61.5%
Asia / Africa 12,805 17,238 34.6%
Total 52,027 74,146 42.5%

Gross profit for the quarter amounted to US$18.0 million representing a gross margin of 48.1%. This compares to a gross margin of 48.2% for the same period in 2006. The increase in selling, general and administrative expenses from US$9.3 million in 2006 to US$12.3 million in the current year is primarily attributable to the impact of the acquisition of the haemostasis product line of bioMerieux in June 2006 and the direct selling operation in France which was established in October 2006. The tax charge for the quarter has reverted to more normal levels following the once off tax credit in quarter 1 associated with the redistribution of inventory around the group.

Commenting on the results, Rory Nealon, Chief Financial Officer, said, "Quarter 2 has seen continued growth in our revenues and operating profits despite slower than expected growth in our antibody business. From quarter 1 to quarter 2 our revenues have increased by 2% after a particularly strong quarter 1 and our EBITDA before share option expenses has increased to US$6.0 million. Our operating margin before share option expense has increased from 10.0% of revenues in quarter 1 to 10.9% in the current quarter.

"The integration of our bioMerieux haemostasis acquisition is proceeding well. Our new production facility has been completed on schedule and the transition agreement with bioMerieux has now finished. We anticipate manufacturing our first batches of bioMerieux product in Quarter 3 as planned."

Ronan O' Caoimh, CEO, commented, "We are pleased with the ongoing growth in our business and are particularly excited with progress in key areas which are fueling our strategic growth.

"In clinical chemistry, we are looking forward to the pending launch of our rapid point of care product in HbA1c which we will market under the Tri-Stat brand. This dynamic platform will be introduced in physician office labs, diabetic clinics, as well as hospital labs. Unique to Tri-stat will be the ability to run three patient samples at the same time. We are seeking a physician office home use clasification in its CLIA waiver from the FDA. Importantly, this classification will grant doctors a reimbursement of approximately $8 more than the same test by our competitors in the market. We expect to launch Tri-stat into the U.S. market in early Quarter 4.

"Recent developments in the HIV point of care industry include the $35m rapid HIV screening initiative that the U.S. Centers for Disease Control and Prevention ('CDC') announced earlier this year. We are very pleased by the additional exposure that the CDC generated around rapid HIV screening through this initiative and the fact that the CDC is making health jurisdiction grantees aware of the market choices available to their programs during this process. We are encouraged by the extent of interest in and validation of our product's key differentiating points, namely its earlier detection capability, higher degree of efficacy and longer shelf life. We expect the $35m in net new annual CDC resources for this new screening initiative to be made available with effect from quarter 4.

In Haemostasis, we remain excited about the prospects for the Destiny Max instrument which will become the newest and most technologically advanced large hospital instrument deployed in the U.S. and Europe for many years. This instrument will address the largest market segment comprising high throughput hospitals. We believe Destiny Max, with high throughput capability together with a unique user interface, will provide very attractive points of differentiation to the older technologies serving this segment today. We are looking for a formal product launch during 2008."

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners. For further information please see the Company's website: www.trinitybiotech.com.

acsalvo (< 20) Submitted: 2/24/2007 12:40:37 PM : Start Price: $10.10 TRIB Score: -39.35

Aids product coming to market

PearlandTX (96.63) Submitted: 11/1/2006 8:10:31 PM : Start Price: $8.91 TRIB Score: -39.47

Positive: Company has performed very well over last two years, but the stock has not. expect the stock to catch up with company performance. Competes well in a clear niche market. Has invested in sales/distribution andshould see results of that investment over next few years.
Negative: Growth by acquisition strategy can dilute shareholder earnings and increase risk. Needs to improve marketing.

BLAISEMD (< 20) Submitted: 10/11/2006 9:40:49 PM : Start Price: $9.40 TRIB Score: -42.40

Home AIDS test kit will be huge